C(N(CC)CC)C.C(OS(OCCC)(=O)=O)CC.C(OC([N:26]1[CH2:31][CH2:30][CH:29]([NH:32][S:33]([C:36]2[CH:45]=[CH:44][C:43]3[NH:42][C:41](=[O:46])[C:40]4[NH:47][CH:48]=[C:49]([C:50]([OH:52])=[O:51])[C:39]=4[C:38]=3[CH:37]=2)(=[O:35])=[O:34])[CH2:28][CH2:27]1)=O)(C)(C)C.N>CN(C)C=O.O>[O:46]=[C:41]1[C:40]2[NH:47][CH:48]=[CH:49][C:39]=2[C:38]2[CH:37]=[C:36]([S:33](=[O:35])(=[O:34])[NH:32][CH:29]3[CH2:28][CH2:27][NH:26][CH2:31][CH2:30]3)[CH:45]=[CH:44][C:43]=2[NH:42]1.[CH2:49]([C:50]([O-:52])=[O:51])[CH2:39][CH3:38]107 μL (0.76 mmol) of triethylamine and 100 μL (0.61 mmol) of di-n-propylsulfate are added to a solution of 150 mg (0.3 mmol) of 8-(1-tert-butoxycarbonyl-piperidin-4-ylsulfamoyl)-4-oxo-4,5-dihydro-3H-pyrrolo[2,3-c]quinoline-1-carboxylic acid dissolved in 2 mL of anhydrous dimethylformamide. The solution is stirred at room temperature for 20 hours then 43 μL (0.3 mmol) of triethylamine and 51 μL (0.3 mmol) of di-n-propylsulfate are added again. Stirring is continued for a further 24 hours and 3 mL of ammonia is added. After stirring for a further 15 minutes, water is added and the product is extracted with dichloromethane. The organic phases are dried over magnesium sulfate, filtered then evaporated. The residue is dissolved in 2 mL of dichloroethane and 1 mL of trifluoroacetic acid. The solution is stirred at room temperature for 1 hour then the solvents are evaporated. The solid is taken up in dichloromethane then triethylamine is added to release the amine. The solvents are evaporated again and the residue is purified by chromatography on silica (eluent chloroform/methanol/ammonia 160/25/4) to give 44 mg (33% in two stages) of 4-oxo-8-(piperidin-4-ylsulfamoyl)-4,5-dihydro-3H-pyrrolo[2,3-c]quinoline-1-propyl carboxylate in the form of a white solid.